Praxis’ essential tremor drug fails interim Phase 3 readoutnews2025-02-28T15:30:27+00:00February 28th, 2025|Endpoints News|
Verve is latest gene editing company to suffer setback, as Vertex walks away from pactnews2025-02-27T16:24:04+00:00February 27th, 2025|Endpoints News|
Kallyope quietly reports Phase 2 obesity data, begins mid-stage migraine trialnews2025-02-27T11:11:16+00:00February 27th, 2025|Endpoints News|
Sorriso Pharmaceuticals outlines Phase 1b ulcerative colitis data for oral antibodynews2025-02-27T10:10:00+00:00February 27th, 2025|Endpoints News|
AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertainnews2025-02-26T16:31:36+00:00February 26th, 2025|Endpoints News|
Regeneron, two Chinese biotechs tout promise of their hearing loss gene therapiesnews2025-02-26T16:30:13+00:00February 26th, 2025|Endpoints News|
Candel’s viral therapy shows promising survival in small pancreatic cancer studynews2025-02-25T20:56:11+00:00February 25th, 2025|Endpoints News|
Emalex clears Phase 3 for Tourette syndrome, will seek FDA approvalnews2025-02-25T20:18:57+00:00February 25th, 2025|Endpoints News|
Alnylam eyes bigger diseases in more tissue types at ‘inflection point’ for siRNAnews2025-02-25T12:00:00+00:00February 25th, 2025|Endpoints News|
FDA lifts hold on Entrada’s Duchenne drug after two yearsnews2025-02-24T16:02:07+00:00February 24th, 2025|Endpoints News|
